A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

NCT05181540 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis showed lack of efficacy

Conditions

Hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: AB-205
OTHER: Placebo

Sponsor

Angiocrine Bioscience

Collaborators

[object Object]